2024 Nasdaq vktx - VDOMDHTMLhtml>. Viking Therapeutics, Inc. Common Stock (VKTX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

 
VKTX U.S.: Nasdaq Viking Therapeutics Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 20, 2023 7:59 p.m. EST Delayed quote $ 11.78 0.01 0.08% After Hours Volume: 20.04K.... Nasdaq vktx

Viking Therapeutics, Inc. (NASDAQ:VKTX) is an American biotechnology company headquartered in San Diego, California. It develops drugs for patients suffering from surgical complications and liver ...Apr 16, 2023 · VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals and the stock ... (NASDAQ: VKTX) Viking Therapeutics's market cap is $978.28M, as of Nov 12, 2023. Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. Viking Therapeutics 's market cap is calculated by multiplying VKTX 's current stock price of $9.78 by VKTX 's total outstanding shares of 100,028,953 .Pfizer (NYSE:PFE) shares hit a new 52-week low on Friday after announcing that its twice-daily oral weight loss candidate danuglipron will not reach late-stage development as a Phase 2 readout ...About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. See Also. Nasdaq MarketSIte. Do Not Sell My Personal ...SAN DIEGO, Oct. 5, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Clinical-stage biotech Viking Therapeutics ( VKTX 6.23%) is having another tough trading session. As of 1:40 p.m. ET Tuesday, Viking's stock was down by 19.8% on higher-than-normal volume ...Viking Therapeutics, Inc. Common Stock (VKTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today ...Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ...Viking Therapeutics, Inc. (NASDAQ:VKTX) is up about 315% over the past one year. Viking Therapeutics, Inc. (NASDAQ:VKTX) in July filed for a mixed securities shelf offering.(NASDAQ: VKTX) Viking Therapeutics's 52-week high was $25.72, and its 52-week low was $3.54. It is currently -49.42% from its 52-week high and 267.51% from its ...Viking Therapeutics, Inc. (NASDAQ:VKTX) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose 8.7%, resulting in a US$167m rise in the company's market ...Viking Therapeutics, Inc. (NASDAQ:VKTX) is an American biotechnology company headquartered in San Diego, California. It develops drugs for patients suffering from surgical complications and liver ...The 36-month beta value for VKTX is also noteworthy at 0.59. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”. The average price estimated by analysts for VKTX is $33.80, which is $21.97 above than the current price.Viking Therapeutics' (NASDAQ:VKTX) shares rose 14% after clinical results from a Phase 1 trial on its obesity drug, VK2735, were released. The study showed that VK2735, ...VKTX Viking Therapeutics Inc Viking Therapeutics to Report Financial Results for Second Quarter 2021 on July 28, 2021SAN DIEGO, Oct. 25, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Viking Therapeutics Inc (NASDAQ:VKTX). 13.01. Delayed Data. As of Dec 01. +0.79 / +6.42%. Today's Change. 3.54. Today|||52-Week Range. 25.72. +38.35%. Year-to- ...Tower Research Capital LLC TRC has reported a significant increase in its holdings of Viking Therapeutics, Inc. (NASDAQ:VKTX) during the first quarter of this year. According to the company’s recent disclosure with the Securities and Exchange Commission, TRC raised its holdings by 262.2%, acquiring an additional 9,391 shares …Viking Therapeutics Inc (NASDAQ: VKTX) (after the close) Thursday . Evelo Biosciences Inc (NASDAQ: EVLO) (before the market open) Baxter International Inc (NYSE: BAX) (before the market open)Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire.VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83.Dec 1, 2023 · View Viking Therapeutics, Inc VKTX investment & stock information. Get the latest Viking Therapeutics, Inc VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Feb 28, 2023 · 784,592. 4.713748. Back to VKTX Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ... Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...Stock Activity Open 12.40 Day Low 11.82 Day High 13.10 52 Wk Low 3.54 52 Wk High 25.72 Avg. Volume 1,501,039 Market Cap 1.22 B Dividend 0.00 ( 0.00%) Beta …Oct 18, 2023 · Viking Therapeutics (NASDAQ:VKTX) is arguably best known for being one of the frontrunners to win the "NASH Dash," i.e. the first company to secure approval to market and sell a drug designed to ... That's the story for Viking Therapeutics ' ( VKTX 6.46%) share price so far this year. The stock jumped nearly 26% year to date by early March. It subsequently gave up all of those gains and then ...To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.VKTX Latest Pre Market Trades · Trending Stocks · Your symbols have been updated · Edit Watchlist · Opt in to Smart Portfolio · Privacy Preference Center. When ...SAN DIEGO, April 7, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Of the funds tracked by Insider Monkey, Peter S. Park's Park West Asset Management has the largest position in Viking Therapeutics, Inc. (NASDAQ:VKTX), worth close to $12 million, accounting for 0 ...The latest price target for Viking Therapeutics ( NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023. The analyst firm set a price target for 32.00 expecting VKTX to rise ...Viking Therapeutics, Inc. (NASDAQ: VKTX) is an American biotechnology company that is focused on the development of novel and orally available therapies for the treatment of metabolic and ...Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the …Viking Therapeutics Stock Price, News & Analysis (NASDAQ:VKTX) $13.01 +0.79 (+6.46%) (As of 12/1/2023 ET) Today's Range $11.82 $13.10 50-Day Range $9.24 …SAN DIEGO, Sept. 11, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for ...Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the ...According to the issued ratings of 9 analysts in the last year, the consensus rating for Viking Therapeutics stock is Buy based on the current 9 buy ratings for VKTX. The average twelve-month price prediction for Viking Therapeutics is $30.25 with a high price target of $37.00 and a low price target of $19.00.Standing squarely in the bull camp, BTIG analyst Justin Zelin rates VKTX a Buy along with a $20 price target. This target puts the upside potential at a whopping 221%. (To watch Zelin’s track ...VKTX Viking Therapeutics Options Ahead of Earnings Analyzing the options chain and the chart patterns of VKTX Viking Therapeutics prior to the earnings report this week, I would consider purchasing the 11usd strike price Calls with an expiration date of 2024-1-19, for a premium of approximately $1.80. Financial News. View the latest Viking Therapeutics Inc. (VKTX) stock price, news, historical charts, analyst ratings and financial information from WSJ.Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 13.01 +0.79 (+6.46%) At close: 04:00PM EST. 13.10 +0.09 (+0.69%) After hours: 07:47PM EST.Viking Therapeutics, Inc. (NASDAQ:VKTX) is a San Diego, California-based biotech company developing therapeutics for patients that are suffering from endocrine and metabolic disorders.SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Dec 1, 2023 · Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today ...According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Viking Therapeutics (NASDAQ:VKTX) spiked in late December, due to recent news indirectly related to the biopharma firm, and its efforts to bring a treatment for non-alcoholic steatohepatitis (or ...Viking Therapeutics, Inc. Common Stock (VKTX). Nasdaq Listed ...VFS. VinFast Auto Ltd. Ordinary Shares. $17.15 -0.84 -4.67%. Find the latest news headlines from Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.Dec 4, 2023 · Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered the stock in the […] Simply Wall St ™. Simply Wall Street Pty Ltd. Level 7, 320 Pitt Street, Sydney. Popular Markets. US AU UK IN CA ZA. About Us Careers. Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927).Viking Therapeutics (NASDAQ:VKTX) is arguably best known for being one of the frontrunners to win the "NASH Dash," i.e. the first company to secure approval to market and sell a drug designed to ...Viking Therapeutics Inc. (NASDAQ: VKTX) Viking Therapeutics was founded in 2012 to create treatments for metabolic and endocrine disorders. This area still has a lot of need, and FDA approval here could catapult the company forward on its own.Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire.Dec 1, 2023 · During the last session, Viking Therapeutics Inc (NASDAQ:VKTX)’s traded shares were 1.77 million, with the beta value of the company hitting 0.59. At the end of the trading day, the stock’s price was $12.22, reflecting an intraday gain of 3.30% or $0.39. The 52-week high for the VKTX share is $ ... Principal Financial Group Inc. bought a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the second quarter, according to the company in its most recent Form 13F filing ...Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA. VKTX - Viking Therapeutics Inc - Stock screener for …Feb 28, 2023 · 784,592. 4.713748. Back to VKTX Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ... View real-time VKTX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...SAN DIEGO, Oct. 5, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...May 18, 2023 · Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics ( VKTX -2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares ... VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals and the stock ...VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ... Mar 29, 2023 · Shares of Viking Therapeutics VKTX have surged almost 70% on Mar 28, after it announced positive clinical data of VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose ... Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher Tuesday after the company reported results from its Phase 1 trial of VK2735 for the potential treatment of various metabolic disorders.Label. Value. Powered by Nasdaq Data Link. Name. Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Viking Therapeutics (NASDAQ:VKTX) stock is taking off o... InvestorPlace - Stock Market News, Stock Advice & Trading Tips Viking Therapeutics (NASDAQ...Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... Oct 25, 2023Fintel reports that on August 8, 2023, Stifel reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation.. Analyst Price Forecast Suggests 142.45% Upside. As of August 2 ...VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 94% based on the firm’s underlying fundamentals and the stock ...Fiscal Q3 2023 ended 9/30/23. Reported on 10/25/23. Get the latest Viking Therapeutics Inc (VKTX) real-time quote, historical performance, charts, and other financial information to …Viking Therapeutics, Inc. (NASDAQ:VKTX) is up about 315% over the past one year. Viking Therapeutics, Inc. (NASDAQ:VKTX) in July filed for a mixed securities shelf offering.That's the story for Viking Therapeutics ' ( VKTX 6.46%) share price so far this year. The stock jumped nearly 26% year to date by early March. It subsequently gave up all of those gains and then ...Nasdaq vktx

Feb 9, 2023 · Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Results Conference Call February 8, 2023 4:30 AM ETCompany Participants. Stephanie Diaz - Investor Relations. Brian Lian - President and Chief ... . Nasdaq vktx

nasdaq vktx

According to the issued ratings of 9 analysts in the last year, the consensus rating for Viking Therapeutics stock is Buy based on the current 9 buy ratings for VKTX. The average twelve-month price prediction for Viking Therapeutics is $30.25 with a high price target of $37.00 and a low price target of $19.00.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb …Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...Market Cap. $1.3B. Currency in USD. Quote data delayed by at least 15 minutes.Viking Therapeutics. Market Cap. $1B. Today's Change. (1.85%) $0.21. Current Price. $11.56. Price as of November 22, 2023, 4:00 p.m. ET. You’re reading a free article with opinions that may ...("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today ...Simply Wall St ™. Simply Wall Street Pty Ltd. Level 7, 320 Pitt Street, Sydney. Popular Markets. US AU UK IN CA ZA. About Us Careers. Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927).About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. See Also. Nasdaq MarketSIte. Do Not Sell My Personal ...Viking Therapeutics (NASDAQ:VKTX) - Although it is a small-cap biotech firm Viking Therapeutics is a company that is involved in an interesting niche. It is involved in treating endocrine and metabolic disorders. At this point in time, ...SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the ...Clinical-stage biotech Viking Therapeutics ( VKTX 6.23%) is having another tough trading session. As of 1:40 p.m. ET Tuesday, Viking's stock was down by 19.8% on higher-than-normal volume ...He does not neglect the obesity-centered candidate VK2735, however, and writes, “We view VKTX’s lead candidate THR-β agonist VK2809 for NASH as similar to Madrigal Pharmaceutical’s MGL-3196 ...SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences.Feb 9, 2023 · Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Results Conference Call February 8, 2023 4:30 AM ETCompany Participants. Stephanie Diaz - Investor Relations. Brian Lian - President and Chief ... Nov 2, 2023 · SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ... Mar 16, 2023 · Shares of Viking Therapeutics (NASDAQ: VKTX) are trading down over 15% late into Tuesday's session, in a move linked to the disappointing clinical data posted by VKTX's competitor Altimmune, Inc ... Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Tuesday after the company presented new data from its Phase 2b studySAN DIEGO, April 3, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Based on analysts offering 12 month price targets for VKTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . 03 Nov, 2021, 16:05 ET. SAN DIEGO, Nov. 3, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel ...Since the year began, shares of Viking Therapeutics (NASDAQ:VKTX) exploded from about $8 to about $25 a share. All thanks to its potential treatment for obesity, VK2735.Shares of NASDAQ VKTX opened at $13.01 on Monday. Viking Therapeutics has a 12 month low of $3.54 and a 12 month high of $25.72. The stock has a 50 day …Viking Therapeutics (NASDAQ:VKTX) is a great speculative biotech play to look into. The reason why I state that is because I believe it has huge potential as a long-term play.VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83.Viking Therapeutics, Inc. (NASDAQ:VKTX) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose 8.7%, resulting in a US$167m rise in the company's market ...Viking Therapeutics (NASDAQ:VKTX) is arguably best known for being one of the frontrunners to win the "NASH Dash," i.e. the first company to secure approval to market and sell a drug designed to ...Dec 1, 2023 · Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire. Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the ...Fintel reports that on May 8, 2023, HC Wainwright & Co. reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation. Analyst Price Forecast Suggests 20.92% Upside. As of ...Strong Quarter-End Cash Position of $376M. SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the ...According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...Viking Therapeutics (VKTX 6.46%) seeks to develop new treatments for metabolic and endocrine diseases. Lead drug candidate VK-2809 recently entered a phase 2b clinical trial at the end of last ...View real-time VKTX stock price and news, ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with volume of at least 50,000.VKTX has move up from $4.00 a share to nearly $11.00 a share, largely in sympathy since those Madrigal trial results were announced. Therefore, I have taken profits on most of my small stake in VKTX.Fintel reports that on May 8, 2023, HC Wainwright & Co. reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation. Analyst Price Forecast Suggests 20.92% Upside. As of ...The "Mad Money" host said Viking Therapeutics, Inc. (NASDAQ:VKTX) is a "very good spec, but you have to understand it could be wiped out or go up a lot." Price Action: ...View the latest Viking Therapeutics Inc. (VKTX) stock price, news, historical charts, analyst ratings and financial information from WSJ.Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... Oct 25, 2023Viking Therapeutics, Inc. (NASDAQ:VKTX) is an American biotechnology company headquartered in San Diego, California. It develops drugs for patients suffering from surgical complications and liver ...Fiscal Q3 2023 ended 9/30/23. Reported on 10/25/23. Get the latest Viking Therapeutics Inc (VKTX) real-time quote, historical performance, charts, and other financial information to …May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease. With ...Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the …SAN DIEGO, Oct. 5, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Jul 29, 2023 · Viking Therapeutics, Inc. (NASDAQ:VKTX), based in San Diego, California, is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and ... EPS Estimate Trends. Current. N/A. 1 Month Ago. -$0.24. 3 Months Ago. -$0.24. Viking Therapeutics Inc. analyst estimates, including VKTX earnings per share estimates and analyst recommendations.Shares of Viking Therapeutics VKTX have surged almost 70% on Mar 28, after it announced positive clinical data of VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose ...SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor …Viking Therapeutics, Inc. (NASDAQ:VKTX) is a San Diego, California-based biotech company developing therapeutics for patients that are suffering from endocrine and metabolic disorders.Apr 4, 2023 · Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ... צפה בגרף ‎Viking Therapeutics, Inc.‎ בזמן אמת כדי לעקוב אחר תנועת מחיר המניה. תמצא תחזיות שוק, ‎VKTX‎ וחדשות שוק כלכליות.SAN DIEGO, Oct. 23, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Nasdaq +78.81(+0.55%) Russell 2000 1,862.64 +53.62(+2.96%) Crude Oil 74.38 -1.58(-2.08%) Gold 2,091.70 +34.50(+1.68%) Advertisement Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real... See moreYou can practice and explore trading VKTX stock methods without spending real money on the virtual. Webull offers VKTX Ent Holdg (VKTX) historical stock prices, in-depth market analysis, NASDAQ: VKTX real-time stock quote data, in-depth charts, free VKTX options chain data, and a fully built financial calendar to help you invest smart. Shares of Viking Therapeutics (NASDAQ:VKTX) are making headlines this week after an announcement from Gilead Sciences (NASDAQ:GILD), that one of its drugs did not meet the primary endpoints of its ...VKTX Related ETFs ; VTI, 0%, +3.43% ; Total Stock Market ETF Vanguard ; DWAS, 0.82%, -2.47% ; DWA Smallcap Momentum Invesco ETF ...Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added ~39% pre-market Tuesday after announcing that its obesity candidate VK2735 led to an average body weight reduction of up to ~8% in a ...Viking Therapeutics (NASDAQ:VKTX) shares gained over 5% in extended trading on Monday after the drugmaker reported positive findings from an ongoing study of its lead drug candidate, VK2809.VK2809 ...9 brokers have issued 1 year target prices for Viking Therapeutics' shares. Their VKTX share price targets range from $19.00 to $37.00. On average, they predict the company's stock price to reach $30.25 in the next twelve months. This suggests a possible upside of 132.5% from the stock's current price.VKTX Viking Therapeutics Options Ahead of Earnings Analyzing the options chain and the chart patterns of VKTX Viking Therapeutics prior to the earnings report this week, I would consider purchasing the 11usd strike price Calls with an expiration date of 2024-1-19, for a premium of approximately $1.80.Stock Information NASDAQVKTX $12.52 NASDAQVKTX Open $12.01 Change $0.69 (5.83%) Day's Range $12.01 - $12.67 52-Week Range $3.54 - $25.72 Volume 562.4K …SAN DIEGO, July 6, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...In the news. Yahoo Finance. 3 days ago. Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company.SAN DIEGO, Oct. 23, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Apr 3, 2023 · SAN DIEGO, April 3, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ... XBI, IMGN, VKTX, TGTX: ETF Outflow Alert. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF ...12.28 USD. +6.23%. +8.96%. +30.64%. Nov. 14. Viking Therapeutics' Phase 2b of VK2809 to Treat Non-Alcoholic Steatohepatitis Meets Primary Endpoint; Shares Rise Early. MT. …VKTX Latest Pre Market Trades · Trending Stocks · Your symbols have been updated · Edit Watchlist · Opt in to Smart Portfolio · Privacy Preference Center. When ...5 Best Weight Loss Stocks To Invest In Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2023 Earnings Call Transcript 10 Stocks Wall Street Analysts and Billionaires Are Crazy About 15 Best-Performing ...Jul 26, 2023 · Strong Quarter-End Cash Position of $393M. SAN DIEGO, July 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the ... SAN DIEGO, Jan. 9, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 2b clinical trial of VK2809, the company's novel liver ...Nov 2, 2023 · SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ... Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire.So, the natural question for Viking Therapeutics (NASDAQ:VKTX) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual ...Viking Therapeutics Inc (Symbol: VKTX) saw options trading volume of 5,067 contracts, representing approximately 506,700 underlying shares or approximately 53.5% of VKTX's average daily trading ...... Back to VKTX Overview About News Headlines Nasdaq provides updated worldwide news headlines. Here you can find up-to-the-minute news and analysis of the company …Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 13.01 +0.79 (+6.46%) At close: 04:00PM EST. 13.10 +0.09 (+0.69%) After hours: 07:47PM EST. Roth Capital reduced its price target to $15 from $20 in April 2022, outlining changes to its financial model. Sio Capital’s Q4 2021 stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) was worth $3 ...Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics ( VKTX -2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares ...Viking Therapeutics Inc stock price (VKTX) NASDAQ: VKTX. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert …Shares of NASDAQ VKTX opened at $13.01 on Monday. Viking Therapeutics has a 12 month low of $3.54 and a 12 month high of $25.72. The stock has a 50 day moving average of $10.86 and a 200-day .... Threads stock